FIBRISTAL - Trademark Details
Status: 605 - Abandoned - After Publication
Serial Number
87418777
Word Mark
FIBRISTAL
Status
605 - Abandoned - After Publication
Status Date
2018-10-10
Filing Date
2017-04-20
Mark Drawing
3000 - Illustration: Drawing or design which also includes word(s)/ letter(s)/number(s)
Typeset
Design Searches
050308, 050325 - More than one leaf, including scattered leaves, bunches of leaves not attached to branches. Other leaves.
Published for Opposition Date
2017-09-05
Law Office Assigned Location Code
N50
Employee Name
MAJCHER HARTNETT, MEGA
Statements
Indication of Colors claimed
Color is not claimed as a feature of the mark.
Description of Mark
The mark consists of the word "FIBRISTAL" in lower case letters, with portions of three leaves extending generally upwards from the top of the letter "B".
Goods and Services
Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression; pharmaceutical preparations, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic and anti-inflammatory ointments; ocular wetting solutions, namely, eye drops, artificial tears and pharmaceutical gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and medicated creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, medicated toners, medicated moisturizers, medicated rejuvenators, medicated rehydrating creams, and medicated lotions for the face and body
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
8 - Abandoned
Class Status Date
2018-10-10
Primary Code
005
Correspondences
Name
SUSAN J. HINCHEY
Address
Please log in with your Justia account to see this address.
Trademark Events
Event Date | Event Description |
2017-04-24 | NEW APPLICATION ENTERED IN TRAM |
2017-04-26 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2017-04-27 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
2017-07-17 | ASSIGNED TO EXAMINER |
2017-07-17 | EXAMINERS AMENDMENT -WRITTEN |
2017-07-17 | EXAMINERS AMENDMENT E-MAILED |
2017-07-17 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
2017-07-17 | EXAMINER'S AMENDMENT ENTERED |
2017-07-18 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2017-08-16 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2017-09-05 | PUBLISHED FOR OPPOSITION |
2017-09-05 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
2017-10-31 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
2018-03-26 | TEAS EXTENSION RECEIVED |
2018-03-26 | EXTENSION 1 FILED |
2018-03-26 | EXTENSION 1 GRANTED |
2018-03-28 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2018-09-27 | TEAS EXTENSION RECEIVED |
2018-10-04 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
2018-10-09 | ITU OFFICE ACTION ISSUED FOR EXTENSION REQUEST |
2018-10-09 | TEAS EXPRESS ABANDONMENT RECEIVED |
2018-10-10 | ABANDONMENT - AFTER PUBLICATION |
2018-10-10 | ABANDONMENT NOTICE MAILED - AFTER PUBLICATION |